Trial Profile

Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD33 CAR-NK Cell therapy-Sichuan Kelun-Biotech Biopharmaceutical (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Dexamethasone
Indications Acute myeloid leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

15 Jun 2023 Results (n=10) presented at the 28th Congress of the European Haematology Association
22 Dec 2021 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.
22 Dec 2021 Planned primary completion date changed from 1 Sep 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com